Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 12 Issue 3, June 2018

Volume 12 Issue 3

In this issue...

• Exploring the infectious disease landscape

• How to protect your life science intellectual property

• Focus on fibrosis

Cover image: Laboratory deal symbol. gunaonedesign, Thinkstock.

How to protect your life science intellectual property

    Feature

  • News Feature |

    Inadequate or unsuitable intellectual property (IP) protection could allow competitors to more easily launch a competing product, jeopardizing the opportunity for meaningful return on investment and consequently potential dealmaking. This feature discusses key factors for biotechnology companies to consider in creating IP strategies to support value.

    • Isobel Finnie
  • Profiles

  • Advertisement Feature |

    Technology-focused life science fund Efung Capital is riding the wave of China’s increase in medical investment and demand for healthcare products and services.

    • Shenzhen Efung Investment
  • Advertisement Feature |

    Promethera Biosciences is developing cell-based therapies to treat major acute and chronic liver diseases. Building on its research into immunomodulatory and antifibrotic allogeneic therapies, the biotech is running clinical development programs in acute-on-chronic liver failure (ACLF) and nonalcoholic steatohepatitis (NASH).

    • Promethera Biosciences
  • Advertisement Feature |

    The National Institutes of Health (NIH) is the world’s largest collection of biomedical research institutions and a global translational powerhouse. The National Cancer Institute’s Technology Transfer Center, through its expertise in managing the commercialization of its own and nine other NIH institutes’ discoveries, is leading the way for those seeking to partner and develop world-class biomedical solutions.

    • National Cancer Institute
  • Advertisement Feature |

    LYFE Capital, based in Shanghai with a US office in Palo Alto, California, is a healthcare investment firm that targets biopharma, medtech, healthcare service and digital health companies.

    • LYFE Capital
  • Advertisement Feature |

    An intravenously administered oncolytic virus platform delivers combinations of therapeutic genes specifically to solid tumors to enable a potent anticancer immune response while minimizing systemic toxicity.

    • PsiOxus Therapeutics Inc
  • Advertisement Feature |

    Halozyme has developed ENHANZE, a recombinant human hyaluronidase-based drug delivery technology that enables and optimizes subcutaneous drug delivery for appropriate coadministered therapeutics.

    • Halozyme
  • Advertisement Feature |

    C-Bridge Capital specializes in the growing Chinese health care market and is using its expertize to identify emerging industry leaders and bring global innovation into China.

    • C-Bridge Capital
  • Advertisement Feature |

    BioCubaFarma, the Cuban organization of Biotechnology and Pharmaceutical Industries, manages the country’s efforts toward manufacturing medicines, diagnostics and medical equipment and providing high quality life science services to improve people’s health. BioCubaFarma serves as a gateway for potential partners and investors interested in accessing the extensive biopharma resources Cuba has to offer.

    • BioCubaFarma

Exploring the infectious disease landscape

    Feature

  • News Feature |

    The market for drugs and vaccines to combat infectious diseases is expanding overall, but with wide variation in sales among its segments. This article analyzes the products, trends and dealmaking underlying these changes.

    • Antonio Iervolino
  • Profiles

  • Advertisement Feature |

    Anti-infective company VenatoRx Pharmaceuticals has developed injectable and orally bioavailable broad-spectrum antibiotics that could help curb the expansion of antimicrobial resistance. The company is now seeking clinical and commercial partnerships.

    • VenatoRx Pharmaceuticals
  • Advertisement Feature |

    Using its antibiotic renewable technology, Helperby Therapeutics is developing a new class of antibiotics with activity against multidrug-resistant bacteria, including strains with transferable resistance to carbapenems and colistin.

    • Helperby Therapeutics Ltd
  • Advertisement Feature |

    Building on its history of successful collaborations, Sanofi Pasteur, the vaccines global business unit of Sanofi, is seeking partners with a common drive for excellence and pursuit of innovation.

    • Sanofi Pasteur
  • Advertisement Feature |

    YUMAB, a global provider of fully human monoclonal antibody discovery and development, has relocated its headquarters to Germany’s hotspot of infectious research and is advancing new opportunities for the expedited development of prophylactic and therapeutic antibodies and vaccines to fight infectious diseases.

    • YUMAB GmbH
  • Advertisement Feature |

    The Liverpool School of Tropical Medicine’s Research Centre for Drugs and Diagnostics’ public–private partnerships and delivery of translational projects help vulnerable people in resource-poor countries.

    • Liverpool School of Tropical Medicine
  • Advertisement Feature |

    Karius has developed a novel commercial cell-free DNA blood test able to rapidly and accurately detect more than 1,000 pathogens from a standard blood draw.

    • Karius Inc.
  • Advertisement Feature |

    With core competencies in small-molecule drug design and synthesis, Shionogi continues to achieve success in and expand its infectious disease portfolio of both antibacterials and antivirals, many of which are home-grown products.

    • Shionogi Pharmaceutical Research Center
  • Advertisement Feature |

    Quebec-based Medicago is transforming the use of plant-based technologies to rapidly develop and produce novel vaccines and therapeutic proteins.

    • Medicago Inc
  • Advertisement Feature |

    Taking a unique approach by targeting the virus host cell, Ansun BioPharma of San Diego, California is developing lead candidate Fludase (DAS181), which has shown potential for the treatment of parainfluenza, influenza and other viruses, including resistant strains.

    • Ansun Biopharma

Focus on fibrosis

    Feature

  • News Feature |

    Fibrosis-related diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis, have generated a wave of deal and funding activity over recent years. Here, we highlight a selection of these deals.

  • Profiles

  • Advertisement Feature |

    A treatment for fatal lung diseases such as idiopathic pulmonary fibrosis is being developed by Lung Therapeutics. The novel mechanism could have wider applications for other fibrotic diseases.

    • Lung Therapeutics, Inc.
  • Advertisement Feature |

    Promedior, a clinical-stage biotechnology company, is developing immunotherapies to treat fibrosis. The company’s lead product candidate is PRM-151, a recombinant form of human pentraxin-2 formulated for intravenous injection.

    • Promedior, Inc.
  • Advertisement Feature |

    Fibrosis is characterized by the excessive or abnormal accumulation of extracellular matrix within tissue, leading to organ dysfunction and disease in a range of conditions. There is a high level of unmet need given that the limited treatments available offer only modest benefits, and new drugs are urgently needed.

    • PharmAkea

Search

Quick links